 |
Arcellx
David Hilbert - President & CEO
USA | Funding: $622M (+)
Website: http://www.arcellx.com/
Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.
Website: http://www.arcellx.com/
Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.
